Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Imbert

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Advances in Experimental Medicine and Biology|October 29, 2020
γδ T Cells in Tumor MicroenvironmentCaroline Imbert, Daniel Olive
Nature Communications|December 24, 2017
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanomaFlorie Bertrand, Anne Montfort, Elie Marcheteau, et al.
Oncotarget|October 7, 2016
Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanomaMarguerite Mrad, Caroline Imbert, Virginie Garcia, et al.
Cancers|August 27, 2021
Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast CancerElie Marcheteau, Thomas Farge, Michaël Pérès, et al.
Cell Reports|July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cellsCarla E Cano, Christine Pasero, Aude De Gassart, et al.
Cancer Immunology Research|September 20, 2024
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell PyroptosisAnne-Charlotte Le Floch, Caroline Imbert, Nicolas Boucherit, et al.
Cell Reports|October 9, 2025
BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cellsEmilien Billon, Caroline Imbert, Damien Bruyat, et al.
Molecular Cancer Therapeutics|November 29, 2018
Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant MelanomasDavid Garandeau, Justine Noujarède, Justine Leclerc, et al.
Nature Communications|January 25, 2020
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1Caroline Imbert, Anne Montfort, Marine Fraisse, et al.
Cancer Immunology Research|March 17, 2021
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy EfficacyAnne Montfort, Florie Bertrand, Julia Rochotte, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Advances in Experimental Medicine and Biology|October 29, 2020
γδ T Cells in Tumor MicroenvironmentCaroline Imbert, Daniel Olive
Nature Communications|December 24, 2017
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanomaFlorie Bertrand, Anne Montfort, Elie Marcheteau, et al.
Oncotarget|October 7, 2016
Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanomaMarguerite Mrad, Caroline Imbert, Virginie Garcia, et al.
Cancers|August 27, 2021
Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast CancerElie Marcheteau, Thomas Farge, Michaël Pérès, et al.
Cell Reports|July 14, 2021
BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cellsCarla E Cano, Christine Pasero, Aude De Gassart, et al.
Cancer Immunology Research|September 20, 2024
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell PyroptosisAnne-Charlotte Le Floch, Caroline Imbert, Nicolas Boucherit, et al.
Cell Reports|October 9, 2025
BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cellsEmilien Billon, Caroline Imbert, Damien Bruyat, et al.
Molecular Cancer Therapeutics|November 29, 2018
Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant MelanomasDavid Garandeau, Justine Noujarède, Justine Leclerc, et al.
Nature Communications|January 25, 2020
Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1Caroline Imbert, Anne Montfort, Marine Fraisse, et al.
Cancer Immunology Research|March 17, 2021
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy EfficacyAnne Montfort, Florie Bertrand, Julia Rochotte, et al.
Pageof 1